Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 2 (1)
P 3 (1)

Trial Status

Active Not Recruiting2
Withdrawn1
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07061977Phase 3Recruiting

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

NCT04580771Phase 2Active Not Recruiting

A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial

NCT04574635Active Not Recruiting

Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer

NCT05093712Withdrawn

Patient-Informed Educational Intervention for the Improvement of Cervical Cancer Literacy

Showing all 4 trials

Research Network

Activity Timeline